Agendia brings new personalized treatment for breast cancer patients

Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint(R), and TargetPrint(TM), has been expanded with BluePrint (TM) to report important additional information on tumor subtypes. This new service is based on an 80-gene signature that identifies the basal-like, luminal-like, and HER2 molecular subtypes in breast cancer tumors.

"Using BluePrint, we will research potentially different responses of therapies to biologically different subgroups together with our customers. In the future, we envision the clinical utility of a combination of BluePrint with MammaPrint's original 70-gene panel," said Richard Bender, MD, FACP, Chief Medical Officer of Agendia. "We believe this combination has great potential to bring the personalized treatment of breast cancer patients to a new level."